about
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSeven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseLong-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survivalExtramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaA phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsPhase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyInterleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsExperimental design and analysis of antibody microarrays: applying methods from cDNA arrays.Highly activated and expanded natural killer cells for multiple myeloma immunotherapyCytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).First thalidomide clinical trial in multiple myeloma: a decade.Clinical trial designs for multiple myeloma.Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.Risk of multiple myeloma in a case-spouse study.Randomized phase III clinical trial designs for targeted agentsThe prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
P50
Q24610430-BE861EBB-4A4B-4F42-8324-C4F315C1B7EFQ24651269-C0B5D18A-1B4D-4694-A476-0804C753E843Q28297940-B5EB91E3-9724-43E2-BE2A-FE673C8BF76DQ33367792-81773D0D-6DFA-419D-8AF2-62DB9ADB86CBQ33401759-BC1CA108-8720-40D6-9CF1-2925E2E94EF9Q33408052-85B45BE6-23F6-48A2-B210-1AEBE8283CF8Q33415840-B975FEA7-A775-41E8-8B0C-330B070EB9D6Q33718273-CEC467B2-DA19-4F9B-ADE8-1E56464AF5F5Q33810494-D77D447B-7D74-441F-82EF-F5A405B885E9Q33887470-44A51D57-45E8-48AD-881A-B651F9E028E0Q33990944-222566F4-21C7-4548-9226-406FBDD779F0Q34122646-520A6837-B64C-4B6A-9B59-4C7047D32EC9Q34571230-C682A2AB-55BB-49B2-8D11-94B9EDC1A5F0Q36099884-10C0DB59-D8ED-4DD9-A9FF-21196EFD2293Q36216203-9515FDC1-07B9-4864-8AB0-1EB326087904Q36384679-CCCBFBD5-9443-45F5-8CA7-F340EA0CC034Q36666793-258E8440-ACA2-4204-BCFD-257CBFC9D7A6Q36697556-6D444EEB-D13C-44A4-884A-EEF3D8AC3F47Q36708969-0AE570F7-89FF-43CC-AB99-5D55DCC6B19AQ36835212-6853C260-50E0-499A-AED9-37E82E75CC22Q36868465-07108057-6015-4E95-B519-8039F85D559CQ36907852-5B1E5B60-FD4B-45E9-BF54-DF60A307BE3AQ36915777-7D3975E2-D1B4-48FF-B213-D41958A73FDDQ37096644-4057611B-B0E4-47E5-95ED-254C9EE05DE4Q37171812-E31BE921-5529-4560-9EA0-B50405F3697DQ37262366-82F94B02-7DB1-4CEE-BF67-35F647473195Q37306614-EDF2CD94-D9B1-4B52-B2AC-EC3541024A19Q37429722-B09BFC5E-4BDF-4D5C-9AA8-AD0C4C6746FCQ38732370-6B34D53D-4469-403E-B0D6-EBBC1C1C5E1CQ38760598-4143787D-E4F8-405D-8739-FB93F7B6D683Q39065872-B9B26AE0-9F37-4BC3-82E1-C7347EEE9DD9Q39449883-F1BE96EB-FEB4-463F-A832-DA599CF0C103Q41284957-4265CAF1-A3CA-4E76-82C9-5EA8B17BB271Q42165255-51233D10-F430-4713-AB97-DDDC74C182BEQ42341707-1DAEB5FD-ECF8-43DF-B45D-F6FAFEFF6F7CQ44810202-C28D841C-6E83-4C59-8581-D8497A06B279Q46868726-1989FE7C-B4CA-4539-A961-5E2FB994874BQ47110205-C7470BAD-F150-41F4-89E6-136A27CF244DQ48675266-DBD5D4C6-22B9-45A8-9D6A-D4B1C9374B75Q52838528-8406996F-680B-43BE-AE59-2BA1462C93C5
P50
name
Antje Hoering
@ast
Antje Hoering
@en
Antje Hoering
@nl
type
label
Antje Hoering
@ast
Antje Hoering
@en
Antje Hoering
@nl
prefLabel
Antje Hoering
@ast
Antje Hoering
@en
Antje Hoering
@nl